Galectin Therapeutics Inc. presented a corporate overview in August 2025, highlighting their focus on developing galectin-based therapeutics aimed at improving the lives of patients with chronic liver diseases and cancer. The presentation emphasized Belapectin, a novel galectin-3 inhibitor with Fast Track Designation, noted for its low toxicity and patent protection through 2032. The company's pipeline is exclusively focused on MASH cirrhosis and portal hypertension, showing significant efficacy in cirrhotic patients without varices. Promising results from the NAVIGATE study indicated a ≥40% reduction in new varices compared to placebo. Additionally, the company's cancer immunotherapy program, involving Belapectin combined with Keytruda, is in progress for treating melanoma and head/neck cancer. The presentation also outlined the discovery program for oral Galectin-3 inhibitors. You can access the full presentation through the link below.